A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS) trial evaluates immunogenicity and safety of one dose of HPV vaccine in Tanzania. The objective of this trial is to demonstrate non-inferiority of immune responses with 1 dose of HPV vaccine compared with the recommended 2 or 3 doses of the same vaccine by evaluating HPV 16/18-specific seropositivity, antibody avidity and memory B cell responses at M36.
The Pneumococcal Conjugate Vaccine Impact Study (PCVIS) is one of the first population-level studies to look at the impact of a pneumococcal conjugate vaccine (PCV10) programme on childhood pneumonia and pneumococcal disease protection in a low- or middle-income country. It is a partnership between the KEMRI-Wellcome Trust Research Programme, the London School of Hygiene & Tropical Medicine, GAVI and the Government of Kenya.
TracVac builds on the results of a phase I clinical trial (NCT02787109) of an adjuvanted Chlamydia trachomatis vaccine (CTH522; Olsen et al 2015, JID PMID2578320) developed by Statens Serum Institut (SSI), Copenhagen. TracVac (www.trachoma-vaccine.org) is a 4 partner (LSHTM, Imperial College London, Commissariat à l’Energie Atomique et aux Energies Alternatives, Paris and SSI) EU sponsored consortium,
National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation is a unique partnership between the London School of Hygiene & Tropical Medicine and Public Health England creating a dynamic fusion of academic research and public health implementation that rapidly translates scientific advances in immunization into measurable benefits for society. The work is organised into 3 themes: 1) Electronic Health Record Research, 2) Modelling, Economics, Evidence-synthesis, 3) Vaccine delivery and confidence.
The purpose of the Vaccine Confidence Project is to monitor public confidence in immunisation programmes by building an information surveillance system for early detection of public concerns around vaccines; by applying a diagnostic tool to data collected to determine the risk level of public concerns in terms of their potential to disrupt vaccine programmes; and, finally, to provide analysis and guidance for early response and engagement with the public to ensure sustained confidence in vaccines and immunisation. This initiative also defines a Vaccine Confidence Index as a tool for mapping confidence globally
The vaccine IS/ID (immunostimlation/immunodynamic) modelling consortium are vaccine developers, drug developers, mathematical modellers and regulators interested in using mathematical modelling methods to improve decisions around vaccine dose development.
A group of mathematical modellers and health economists based at LSHTM and Public Health England who conduct applied epidemiological and economic research to inform public health decisions about vaccination. The mission of this group is to conduct applied epidemiological and economic research to inform public health decisions about vaccination.
Anthropological Exploration of Facilitators and Barriers to Vaccine Deployment and Administration During Disease Outbreaks (AViD)
Headed by Shelley Lees, project AViD is working across DRC, Sierra Leone, Brazil, India and Uganda, adopting both a top-down and bottom-up approach to exploring vaccine acceptance. The project will take a critical anthropological approach to exploring what actions can be taken to optimise vaccine acceptance during a disease outbreak.
Ebola vaccine projects – EBOVAC1, EBOVAC2, EBOVAC3, EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel two-dose preventive vaccine regimen against Ebola Virus Disease (EVD). In a two-dose vaccine regimen, individuals are given a first dose to prime the immune system, and then a second dose which is intended to enhance the immune response and increase the duration of the response.